Compare

Valneva SE/€VLA

1D1W1M3M6MYTD1Y5YMAX

About Valneva SE

Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.
Ticker
€VLA
Sector
Health
Primary listing
PAR
Employees
620
Headquarters
Saint-Herblain, France
Website
valneva.com

Valneva SE Metrics

BasicAdvanced
€465M
-
-€0.88
1.37
-

What the Analysts think about Valneva SE

Analyst ratings (Buy, Hold, Sell) for Valneva SE stock.
Analyst projections of the future price of Valneva SE stock.

Bulls say / Bears say

The Pfizer-partnered Lyme vaccine showed efficacy above 70% in Phase 3, and its European marketing application has been accepted for review. It gives Valneva a significant late-stage pipeline catalyst if regulators approve it. (Pfizer)
Brazil has authorised local production of IXCHIQ through Instituto Butantan, and about 50,000 adults have already received it in a public vaccination campaign. This creates a route into endemic markets beyond travel vaccination. (Valneva)
Valneva maintained its 2026 product-sales guidance of €135–150 million and had €121.5 million in cash at the end of June. It expects restructuring to improve earnings and cash flow from the second half of the year. (Valneva)
The Lyme vaccine missed its primary statistical endpoint: efficacy was 73.2%, but the lower bound of the 95% confidence interval was 15.8%, below the pre-set 20% threshold. A more favourable secondary analysis may help its case, but the primary miss leaves regulatory uncertainty. (Insider Monkey)
Valneva withdrew IXCHIQ’s US application after the FDA suspended its licence following serious adverse events, while European use is now restricted to people at high risk of infection. These limits reduce the vaccine’s commercial reach. (Valneva, HPRA)
First-half revenue fell by about a third to €65.8 million, while the net loss widened to €63.3 million from €20.8 million a year earlier. The results show that Valneva’s current business is not yet covering its costs. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.

Valneva SE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Valneva SE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Valneva SE

Funds
Fund name
Fund size
€VLA weighting
iShares Healthcare Innovation£DRDR
$1.3B0.05%
iShares Healthcare Innovation€2B78
$1.2B0.05%
iShares Healthcare Innovation$HEAL
$1.3B0.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.